Stock DNA
Pharmaceuticals & Biotechnology
CNY 12,905 Million (Large Cap)
17.00
NA
1.78%
-0.08
13.57%
2.36
Revenue and Profits:
Net Sales:
1,048 Million
(Quarterly Results - Jun 2025)
Net Profit:
227 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-6.5%
0%
-6.5%
6 Months
40.9%
0%
40.9%
1 Year
49.14%
0%
49.14%
2 Years
40.18%
0%
40.18%
3 Years
49.73%
0%
49.73%
4 Years
118.02%
0%
118.02%
5 Years
101.09%
0%
101.09%
Zhejiang Jingxin Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
3.23%
EBIT Growth (5y)
12.38%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.05
Sales to Capital Employed (avg)
0.64
Tax Ratio
14.81%
Dividend Payout Ratio
42.33%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
15.55%
ROE (avg)
12.57%
Valuation key factors
Factor
Value
P/E Ratio
17
Industry P/E
Price to Book Value
2.36
EV to EBIT
17.46
EV to EBITDA
11.92
EV to Capital Employed
2.48
EV to Sales
3.14
PEG Ratio
1.92
Dividend Yield
1.78%
ROCE (Latest)
14.20%
ROE (Latest)
13.57%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Sideways
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
1,047.80
946.00
10.76%
Operating Profit (PBDIT) excl Other Income
309.20
247.10
25.13%
Interest
1.70
1.70
Exceptional Items
0.00
0.10
-100.00%
Consolidate Net Profit
226.80
165.40
37.12%
Operating Profit Margin (Excl OI)
212.90%
170.20%
4.27%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 10.76% vs 1.25% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 37.12% vs 19.34% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
4,108.70
3,952.10
3.96%
Operating Profit (PBDIT) excl Other Income
1,023.10
800.70
27.78%
Interest
9.70
9.90
-2.02%
Exceptional Items
-40.20
25.80
-255.81%
Consolidate Net Profit
719.10
623.40
15.35%
Operating Profit Margin (Excl OI)
173.40%
146.60%
2.68%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 3.96% vs 5.62% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 15.35% vs -6.65% in Dec 2023
About Zhejiang Jingxin Pharmaceutical Co., Ltd. 
Zhejiang Jingxin Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






